NC
KRYS icon

NinePointTwo Capital’s Krystal Biotech KRYS Stock Holding History

NinePointTwo Capital’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,186
Closed -$411K – 231
2022
Q1 		$411K Buy
+6,186
New +$386K 0.11% 58

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NinePointTwo Capital's KRYS Position: Q2 2022 in Review

NinePointTwo Capital sold out of Krystal Biotech (KRYS) in Q2 2022, closing a stake of 6,186 shares — an estimated $411K sold.

NinePointTwo Capital first reported a position in KRYS in Q1 2022 and held it in 1 quarter. The position peaked at $411K in Q1 2022. 137 funds tracked by Wall St. Rank hold KRYS as of Q2 2022.

  • NinePointTwo Capital reported no remaining Krystal Biotech position as of Q2 2022 after selling out during the quarter.
  • NinePointTwo Capital sold 6,186 Krystal Biotech shares in Q2 2022, an estimated $411K.
  • NinePointTwo Capital first reported a position in Krystal Biotech in Q1 2022 and held it in 1 quarter.
  • NinePointTwo Capital's Krystal Biotech position peaked at $411K in Q1 2022.
  • 137 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2022.

Based on NinePointTwo Capital's 13F filing for Q2 2022, filed 15 Aug 2022.